Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency
Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effe
Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effe This story matters for Science & Discovery readers tracking science. Reported by phys.org. Read the full original at the source link below.
Originally reported by phys.org. NewsData curates and briefs the science & discovery stories that matter. Our editorial policy →